Cargando…
The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure
Premature ovarian failure (POF) affects 1% of women under 40, leading to infertility. The clinical symptoms of the POF include hypoestrogenism, lack of mature follicles, hypergonadotropinism, and amenorrhea. POF can be caused due to genetic defects, autoimmune illnesses, and environmental factors. T...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070285/ https://www.ncbi.nlm.nih.gov/pubmed/36520408 http://dx.doi.org/10.1007/s12015-022-10493-y |
_version_ | 1785018993590927360 |
---|---|
author | Umer, Amna Khan, Nasar Greene, David Lawrence Habiba, Umm E. Shamim, Sabiha Khayam, Asma Umer |
author_facet | Umer, Amna Khan, Nasar Greene, David Lawrence Habiba, Umm E. Shamim, Sabiha Khayam, Asma Umer |
author_sort | Umer, Amna |
collection | PubMed |
description | Premature ovarian failure (POF) affects 1% of women under 40, leading to infertility. The clinical symptoms of the POF include hypoestrogenism, lack of mature follicles, hypergonadotropinism, and amenorrhea. POF can be caused due to genetic defects, autoimmune illnesses, and environmental factors. The conventional treatment of POF remains a limited success rate. Therefore, an innovative treatment strategy like the regeneration of premature ovaries by using human umbilical cord mesenchymal stem cells (hUC-MSCs) can be a choice. To summarize all the theoretical frameworks for additional research and clinical trials, this review article highlights all the results, pros, and cons of the hUC-MSCs used to treat POF. So far, the data shows promising results regarding the treatment of POF using hUC-MSCs. Several properties like relatively low immunogenicity, multipotency, multiple origins, affordability, convenience in production, high efficacy, and donor/recipient friendliness make hUC-MSCs a good choice for treating basic POF. It has been reported that hUC-MSCs impact and enhance all stages of injured tissue regeneration by concurrently stimulating numerous pathways in a paracrine manner, which are involved in the control of ovarian fibrosis, angiogenesis, immune system modulation, and apoptosis. Furthermore, some studies demonstrated that stem cell treatment could lead to hormone-level restoration, follicular activation, and functional restoration of the ovaries. Therefore, all the results in hand regarding the use of hUC-MSCs for the treatment of POF encourage researchers for further clinical trials, which will overcome the ongoing challenges and make this treatment strategy applicable to the clinic in the near future. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-10070285 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-100702852023-04-05 The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure Umer, Amna Khan, Nasar Greene, David Lawrence Habiba, Umm E. Shamim, Sabiha Khayam, Asma Umer Stem Cell Rev Rep Article Premature ovarian failure (POF) affects 1% of women under 40, leading to infertility. The clinical symptoms of the POF include hypoestrogenism, lack of mature follicles, hypergonadotropinism, and amenorrhea. POF can be caused due to genetic defects, autoimmune illnesses, and environmental factors. The conventional treatment of POF remains a limited success rate. Therefore, an innovative treatment strategy like the regeneration of premature ovaries by using human umbilical cord mesenchymal stem cells (hUC-MSCs) can be a choice. To summarize all the theoretical frameworks for additional research and clinical trials, this review article highlights all the results, pros, and cons of the hUC-MSCs used to treat POF. So far, the data shows promising results regarding the treatment of POF using hUC-MSCs. Several properties like relatively low immunogenicity, multipotency, multiple origins, affordability, convenience in production, high efficacy, and donor/recipient friendliness make hUC-MSCs a good choice for treating basic POF. It has been reported that hUC-MSCs impact and enhance all stages of injured tissue regeneration by concurrently stimulating numerous pathways in a paracrine manner, which are involved in the control of ovarian fibrosis, angiogenesis, immune system modulation, and apoptosis. Furthermore, some studies demonstrated that stem cell treatment could lead to hormone-level restoration, follicular activation, and functional restoration of the ovaries. Therefore, all the results in hand regarding the use of hUC-MSCs for the treatment of POF encourage researchers for further clinical trials, which will overcome the ongoing challenges and make this treatment strategy applicable to the clinic in the near future. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2022-12-15 2023 /pmc/articles/PMC10070285/ /pubmed/36520408 http://dx.doi.org/10.1007/s12015-022-10493-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Umer, Amna Khan, Nasar Greene, David Lawrence Habiba, Umm E. Shamim, Sabiha Khayam, Asma Umer The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure |
title | The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure |
title_full | The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure |
title_fullStr | The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure |
title_full_unstemmed | The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure |
title_short | The Therapeutic Potential of Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure |
title_sort | therapeutic potential of human umbilical cord derived mesenchymal stem cells for the treatment of premature ovarian failure |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070285/ https://www.ncbi.nlm.nih.gov/pubmed/36520408 http://dx.doi.org/10.1007/s12015-022-10493-y |
work_keys_str_mv | AT umeramna thetherapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT khannasar thetherapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT greenedavidlawrence thetherapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT habibaumme thetherapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT shamimsabiha thetherapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT khayamasmaumer thetherapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT umeramna therapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT khannasar therapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT greenedavidlawrence therapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT habibaumme therapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT shamimsabiha therapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure AT khayamasmaumer therapeuticpotentialofhumanumbilicalcordderivedmesenchymalstemcellsforthetreatmentofprematureovarianfailure |